Download Category: Documents & Studies

This study provided data to support that CofixRX Nasal Spray is 99.9% effective against SARS-CoV-2, 100% effective against Influenza B and RSV, and 94% effective against HRV-14. The combination of ingredients in CofixRX is highly virucidal against all four of the viruses tested in this laboratory analysis.

The laboratory analysis demonstrated that CofixRX achieved an LRV of 2.9+ 0.4, which indicates that 99.9% of the virus was killed after coming into contact with CofixRX for 45 seconds. Against influenza B, CofixRX achieved an LRV of > 5, indicating 100% effectiveness. CofixRX achieved an LRV of 1.2 against HRV-14, and an LRV > 2 against RSV. This translates to 94% effectiveness against HRV-14, which is associated with the common cold; effectiveness was 100% against RSV, which is an important cause of morbidity in the pediatric population.

CofixRX nasal spray was evaluated against two SARS-CoV-2 (Covid) variants of concern: Delta and Omicron. Virus killing tests were performed by the Institute for Antiviral Research at Utah State University with conditions that would mimic a standard dosage of CofixRX applied per manufacturer’s instructions. The procedure and results are detailed in the official report explaining that CofixRX Nasal Spray is >99.5% effective against SARS-CoV-2 variants of concern in this laboratory analysis. These new results add to previous test data that revealed CofixRX is also 100% effective against the viruses Influenza B (“flu”) and RSV (“respiratory syncytial virus”) and 94% effective against HRV-14 (“human rhinovirus B14”). The study proves that the combination of ingredients, including povidone-iodine, in CofixRX is therefore highly virucidal against four distinct viruses tested, including two major variants of concern for SARS-CoV-2: Delta and Omicron.

This is a one-pager resume -easy to print, read, and share- based on the report from the Institute for Antiviral Research at Utah State University presents the results from testing the virucidal effect of CoFixRx Nasal Spray against SARS-CoV-2 (Covid-19), Influenza B (the flu), HRV-14 (common cold), and RSV.

The report from the Institute for Antiviral Research at Utah State University presents the results from testing the virucidal (Virucidal is defined by Merriam Webster’s dictionary as “having the capacity to or tending to destroy or inactivate viruses.”) effect of CoFixRx Nasal Spray against SARS-CoV-2 (Covid-19), Influenza B (the flu), HRV-14 (common cold), and RSV.

A renewed and updated independent in-vitro study performed by one of the most reputable research institutes in the country, specifically targeting the CofixRX Nasal Spray efficacy against the SARS-Cov-2 virus and its most recent and highly infectious variants, Delta and Omicron. The study also certifies the unrelenting undiminishable efficacy and strength of the product 6 and 24 hours after its first application.

A Review of Safety in the COVID-19 Era of PVP-I topically applied to the nasal and oral cavity.

The SARS-CoV-2 – or novel coronavirus – enters in human body through nose and mouth, stays there for a while. Then binds with ACE2 receptor, enters inside cell, multiply there and manifests. It is already established that PVP-I is a strong microbicidal (chemical) agent, having 99.99% virucidal efficacy in its only 0.23% concentration, irrespective of all known viruses, even in SARS-CoV-2 (in vitro)

Povidone-iodine (PVP-I) is a time-tested antiseptic agent with excellent virucidal (99.99%) properties. Repurposing it against coronavirus disease-19 (COVID-19) is a relatively newer concept and has been sparsely tested in vivo. The most common route of entry of severe acute respiratory syndrome coronavirus 2 (SARS CoV-2) is the nasopharynx. Hence, it was targeted to prevent access and contamination of the nasopharynx by several protective measures, including facemasks. Averting colonization of the virus could be one of the best options to reduce the incidence of infection.

An important independent study from one of the most reputable research institute in the country focused on CofixRX Nasal Spray efficacy against the SARS-Cov-2 in a in-vitro study.

The report from the Institute for Antiviral Research at Utah State University presents the results from testing the virucidal (Virucidal is defined by Merriam Webster’s dictionary as “having the capacity to or tending to destroy or inactivate viruses.”) effect of CofixRx Nasal Spray against SARS-CoV-2 (Covid-19), Influenza B (the flu), HRV-14 (common cold), and RSV.